Skip to content

The effect of Seidlitzia rosmarinus in prevention of the incidence of recurrent cystitis in women of reproductive ages: a randomized controlled trial

The effect of Seidlitzia rosmarinus in prevention of the incidence of recurrent cystitis in women of reproductive ages: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201705146582N30
Enrollment
126
Registered
2017-07-27
Start date
2017-07-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent cystitis. cystitis

Interventions

In the placebo group, the capsule contains 500 mg of starch 3 times a day, half an hour after lunch, lunch and dinner for 2 months.
Intervention 1: In the intervention group, the capsule contains 500 mg of Eshnan herb powder orally 3 times a day, half an hour after breakfast, lunch and dinner for 2 months. Intervention 2: In the p
Treatment - Drugs
Placebo
In the intervention group, the capsule contains 500 mg of Eshnan herb powder orally 3 times a day, half an hour after breakfast, lunch and dinner for 2 months.

Sponsors

vice chancellor for reaserch, University Of Tabriz Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Cystitis infection twice or more than twice in six months, three or more than three times in the past year; Women of childbearing age (15-49 years); Do not use antibiotics over the past month; No use of Immunosuppressive drugs; Willingness to participate in the study; Having a phone number to track; Lack of participation in other similar studies. Exclusion criteria: Postmenopausal women, pregnant and lactating women; Having metabolic, malignant, liver disease and anatomical disorders (Hydronephrosis, kidney stones, and Urethrosele) and functional genital tract (Neurogenic bladder); Recent and concurrent use of other herbal medicines; Hypertension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cystitis incidence. Timepoint: At the end of 2, 4 and 6 months after the intervention began. Method of measurement: Urine/Culture.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahin Kamalifard

Nursing and Midwifery, Tabriz University of Medical Sciences

kamalifardm@tbzmed.ac.ir+98 41 3479 6770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026